EHP-101
| CAS No. | 1818428-24-8 | Cat. No. | BCP43165 |
| Name | EHP-101 | ||
| Synonyms | EHP101; EHP 101; VCE-004; VCE004; VCE 004; VCE-004.8; VCE004.8; VCE 004.8; | ||
| Formula | C28H35NO3 | M. Wt | 433.58 |
| Description | EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. | ||
| Pathways | Cell Cycle/DNA Damage GPCR/G Protein | ||
| Targets | Cannabinoid Receptor PPAR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.